{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:50:33Z","timestamp":1793994633125,"version":"4.8.0"},"reference-count":18,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK"},{"name":"Region Stockholm"},{"DOI":"10.13039\/501100007949","name":"Swedish Rheumatism Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023670","name":"Nyckelfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023670","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Professor Nanna Svartz Foundation"},{"name":"Ulla and Roland Gustafsson Foundation"},{"name":"King Gustaf V\u2019s 80-year Foundation"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,5,31]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Objective<\/jats:title>\n To evaluate Definition Of Remission In SLE (DORIS) and Lupus Low Disease Activity State (LLDAS) attainment with belimumab versus placebo in a dataset of pooled phase III clinical trials in systemic lupus erythematosus (SLE) using modified definitions that excluded the glucocorticoid (GC) component (\u2018non-GC-DORIS\u2019 and \u2018non-GC-LLDAS\u2019) as the trials lacked mandated GC tapering protocols.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this post hoc analysis, data of adults with SLE receiving belimumab (10 mg\/kg\/month intravenously or 200 mg\/week subcutaneously) or placebo plus standard therapy were pooled from five clinical trials (BLISS-76 (\n NCT00410384<\/jats:ext-link>\n ), BLISS-52 (\n NCT00424476<\/jats:ext-link>\n ), North East Asia (\n NCT01345253<\/jats:ext-link>\n ), BLISS-SC (\n NCT01484496<\/jats:ext-link>\n ) and EMBRACE (\n NCT01632241<\/jats:ext-link>\n )). Non-GC-DORIS and non-GC-LLDAS attainment rates (calculated based on SLE Disease Activity Index 2000 and Physician\u2019s Global Assessment only) with belimumab versus placebo were compared up to week 52 in the overall population and in patient subgroups of interest.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Non-GC-DORIS and non-GC-LLDAS attainment at week 52 were significantly higher with belimumab (n=1869) versus placebo (n=1217; non-GC-DORIS: 18% vs 13%, risk ratio, RR (95% CI): 1.44 (1.20 to 1.71); p<0.001; non-GC-LLDAS: 32% vs 21%, RR (95%\u2009CI): 1.50 (1.32 to 1.71); p<0.001). Similar results were observed across most analysed patient subgroups; at week 52, differences were generally greater in the high versus low disease activity subgroups and Asian and White subgroups exhibited significantly higher attainment with belimumab versus placebo.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Belimumab was associated with higher attainment of DORIS remission and LLDAS excluding the GC component versus placebo; attainment rates were approximately twofold higher than those previously reported using the full definitions.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006624","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:12:03Z","timestamp":1783084323000},"page":"e006624","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632241","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632241","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01345253","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01484496","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01632241","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-5395","authenticated-orcid":false,"given":"Ioannis","family":"Parodis","sequence":"first","affiliation":[{"name":"Department of Medicine Solna, Division of Rheumatology, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"},{"name":"Faculty of Medicine and Health, Department of Rheumatology, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Lindblom","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Division of Rheumatology, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A","family":"Levy","sequence":"additional","affiliation":[{"name":"GSK, Global Medical Affairs, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Tsoi","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Division of Rheumatology, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0835-1406","authenticated-orcid":false,"given":"Margherita","family":"Zen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysis","family":"Nikolopoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Division of Rheumatology, Karolinska Institutet, Karolinska University Hospital, and Center for Molecular Medicine (CMM), Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther","family":"Khamashta","sequence":"additional","affiliation":[{"name":"GSK, Medical Affairs, Dubai, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"GSK, Research & Development, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Askanase","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[{"name":"University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026070306101193000_12.3.e006624.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678"},{"key":"2026070306101193000_12.3.e006624.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"2026070306101193000_12.3.e006624.3","unstructured":"GSK . Benlysta prescribing information [online]. 2024. Available: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MG-IFU.PDF"},{"key":"2026070306101193000_12.3.e006624.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026070306101193000_12.3.e006624.5","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026070306101193000_12.3.e006624.6","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30037-2"},{"key":"2026070306101193000_12.3.e006624.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2026070306101193000_12.3.e006624.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2026070306101193000_12.3.e006624.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2026070306101193000_12.3.e006624.10","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026070306101193000_12.3.e006624.11","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of Black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026070306101193000_12.3.e006624.12","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2665-9913(24)00162-0","article-title":"Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials","volume":"6","author":"Parodis","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026070306101193000_12.3.e006624.13","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1016\/S2665-9913(24)00231-5","article-title":"Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab","volume":"6","author":"Bertsias","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026070306101193000_12.3.e006624.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070367"},{"key":"2026070306101193000_12.3.e006624.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2026070306101193000_12.3.e006624.16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/acr.25528","article-title":"American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026070306101193000_12.3.e006624.17","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026070306101193000_12.3.e006624.18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kead696","article-title":"Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients","volume":"64","author":"Altab\u00e1s-Gonz\u00e1lez","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:12:13Z","timestamp":1783084333000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2025-006624"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006624","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}